循环肿瘤细胞在肝细胞癌中的临床应用研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.11.017

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (11): 1844-1848.DOI: 10.3760/cma.j.issn.1007-1245.2024.11.017

循环肿瘤细胞在肝细胞癌中的临床应用研究进展

朱鹏¹ 吴莉莉¹ 郭世民²

¹遂宁市第一人民医院消化内科，遂宁　629000；²联勤保障部队第九八九医院感染科，洛阳　471000

收稿日期:2023-03-09 出版日期:2024-06-01 发布日期:2024-06-25
通讯作者: 郭世民，Email：190880818@qq.com
基金资助:
四川省医学青年创新科研课题计划（Q19033）；四川省中医管理局中医药专项研究课题（2020JC0122）

Research progress of clinical application of circulating tumor cells in hepatocellular carcinoma

Zhu Peng¹, Wu Lili¹, Guo Shimin²

¹Department of Gastroenterology, Suining First People's Hospital, Suining 629000, China; ²Department of Infectious Diseases, 989th Hospital of Joint Logistic Support Force, Luoyang 471000, China

Received:2023-03-09 Online:2024-06-01 Published:2024-06-25
Contact: Guo Shimin, Email: 190880818@qq.com
Supported by:
Sichuan Medical Youth Innovation Research Project (Q19033); Special Research Project of Traditional Chinese Medicine of Sichuan Provincial Administration of Traditional Chinese Medicine (2020JC0122)

摘要/Abstract

摘要：

肝细胞癌（hepatocellular carcinoma，HCC）是常见的消化系统恶性肿瘤之一，具有起病隐匿、恶性程度高、临床预后差的特点。对HCC的早期诊断及准确评估可以有效指导临床实施针对性的干预措施，从而最大限度地改善患者的临床总体预后。循环肿瘤细胞（circulating tumor cell，CTC）检测属于新型液体活检技术的重要组成，其检测方法简便，结果准确可靠，在一定程度上可以替代活组织检查作为HCC诊断的指标。同时，通过CTC检测在HCC患者临床预后评估，尤其是手术患者术后复发评估方面也显示出了重要的应用价值。随着CTC检测技术的不断发展，其用于HCC临床诊治方面的价值也将得到进一步的拓展，从而使更多的HCC患者从中获益。

关键词:

肝细胞癌, 体液活检, 循环肿瘤细胞, CellSearch^?, 诊断, 预后

Abstract:

Hepatocellular carcinoma (HCC) is one of the common malignant tumors of the digestive system, characterized by insidious onset, high malignancy, and poor prognosis. Early diagnosis and accurate evaluation of HCC can effectively guide clinical treatment, so as to improve the patients' overall clinical prognosis. Circulating tumor cell (CTC) testing is an important part of the liquid biopsy technology. CTC detection is a simple and accurate method, and can replace biopsy in diagnosing HCC partly. At the same time, CTC detection has also shown important application value in the clinical prognosis assessment of HCC patients, especially in the evaluation of postoperative recurrence of surgical patients. With the continuous development of CTC detection technology, its value in the clinical diagnosis and treatment of HCC will be further expanded, so that more HCC patients can benefit from it.

Key words:

Hepatocellular carcinoma, Liquid biopsy, Circulating tumor cells, CellSearch^?, Diagnosis, Prognosis

朱鹏吴莉莉郭世民.

循环肿瘤细胞在肝细胞癌中的临床应用研究进展 [J]. 国际医药卫生导报, 2024, 30(11): 1844-1848.

Zhu Peng, Wu Lili, Guo Shimin.

Research progress of clinical application of circulating tumor cells in hepatocellular carcinoma [J]. International Medicine and Health Guidance News, 2024, 30(11): 1844-1848.

参考文献

[1] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. DOI: 10.1016/S0140-6736(22)01200-4.
[2] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[3] Kinsey E, Lee HM. Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape [J]. Cancers (Basel), 2024, 16(3): 666. DOI: 10.3390/cancers16030666
[4] Panneerselvam S, Wilson C, Kumar P, et al. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options [J]. Cell Adh Migr, 2023, 17(1): 1-21. DOI: 10.1080/19336918.2023.2258539.
[5] Manea I, Iacob R, Iacob S, et al. Liquid biopsy for early detection of hepatocellular carcinoma[J]. Front Med (Lausanne), 2023, 10: 1218705. DOI: 10.3389/fmed.2023.1218705.
[6] Zhou Z, Xu X, Liu Y, et al. Liquid biopsy in hepatocellular carcinoma [J]. Methods Mol Biol, 2023, 2695: 213-225. DOI: 10.1007/978-1-0716-3346-5_14.
[7] Chen CL, Hernandez JC, Uthaya Kumar DB, et al. Profiling of circulating tumor cells for screening of selective inhibitors of tumor-initiating stem-like cells [J]. Adv Sci (Weinh), 2023, 10(14): e2206812. DOI: 10.1002/advs.202206812.
[8] Espejo-Cruz ML, Gonzalez-Rubio S, Zamora-Olaya J, et al. Circulating tumor cells in hepatocellular carcinoma: a comprehensive review and critical appraisal [J]. Int J Mol Sci, 2021, 22(23): 13073. DOI: 10.3390/ijms222313073.
[9] 赵洁敏,左万里,廖悦华. 循环肿瘤细胞在非小细胞肺癌患者中的水平及其与肿瘤标志物的关系研究[J]. 国际医药卫生导报, 2022, 28(2): 212-214. DOI:10.3760/cma.j.issn.1007-1245.2022.02.016.
[10] Sun B, Ji WD, Wang WC, et al. Circulating tumor cells participate in the formation of microvascular invasion and impact on clinical outcomes in hepatocellular carcinoma[J]. Front Genet, 2023, 14: 1265866. DOI: 10.3389/fgene.2023.1265866.
[11] De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis [J]. Trends Pharmacol Sci, 2019, 40(3): 172-186. DOI: 10.1016/j.tips.2019.01.006.
[12] Xiao J, Pohlmann PR, Isaacs C, et al. Circulating tumor cells: technologies and their clinical potential in cancer metastasis [J]. Biomedicines, 2021, 9(9):1111. DOI: 10.3390/biomedicines9091111.
[13] David P, Mittelstädt A, Kouhestani D, et al. Current applications of liquid biopsy in gastrointestinal cancer disease-from early cancer detection to individualized cancer treatment [J]. Cancers (Basel), 2023, 15(7): 1924. DOI: 10.3390/cancers15071924.
[14] Smit DJ, Schneegans S, Pantel K. Clinical applications of circulating tumor cells in patients with solid tumors [J]. Clin Exp Metastasis, 2024. DOI: 10.1007/s10585-024-10267-5.
[15] Stergiopoulou D, Markou A, Strati A, et al. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer [J]. Sci Rep, 2023, 13(1): 1258. DOI: 10.1038/s41598-022-25400-1.
[16] Riethdorf S, O'Flaherty L, Hille C, et al. Clinical applications of the CellSearch platform in cancer patients [J]. Adv Drug Deliv Rev, 2018, 125: 102-121. DOI: 10.1016/j.addr.2018.01.011.
[17] Nicolazzo C, Gradilone A, Loreni F, et al. EpCAMlow circulating tumor cells: gold in the waste [J]. Dis Markers, 2019: 1718920. DOI: 10.1155/2019/1718920.
[18] Wang PX,Sun YF,Jin WX,et al. Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX((R)) -i120 Platform: a prospective study[J]. Mol Oncol, 2021, 15(9): 2345-2362. DOI: 10.1002/1878-0261.12876.
[19] Xia W, Li H, Li Y, et al. In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads[J]. Nano Lett, 2021, 21(1): 634-641. DOI: 10.1021/acs.nanolett.0c04180.
[20] Huang XY, Li F, Li TT, et al. A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma [J]. J Nanobiotechnology, 2023, 21(1): 25. DOI: 10.1186/s12951-023-01783-9.
[21] 欧洋,高德海,王振丹,等. CTC-Biopsy系统检测肿瘤患者外周血CTC 临床应用可行性研究[J]. 中华肿瘤防治杂志,2019,26(1):56-60. DOI: 10.16073/j.cnki.cjcpt. 2019.01.011.
[22] Salehi M, Lavasani ZM, Keshavarz Alikhani H, et al. Circulating tumor cells as a promising tool for early detection of hepatocellular carcinoma [J]. Cells, 2023, 12(18): 2260. DOI: 10.3390/cells12182260.
[23] Shaik MR, Sagar PR, Shaik NA, et al. Liquid biopsy in hepatocellular carcinoma: the significance of circulating tumor cells in diagnosis, prognosis, and treatment monitoring [J]. Int J Mol Sci, 2023, 24(13): 10644. DOI: 10.3390/ijms241310644.
[24] Cui K, Ou Y, Shen Y, et al. Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): a systematic review and meta-analysis [J]. Medicine (Baltimore), 2020, 99(40):e22242. DOI: 10.1097/MD.0000000000022242.
[25] Debnath P, Dalal K, Dalal B, et al. Characterization of circulating tumor cells using imaging flow cytometry in liver disease patients [J]. J Clin Exp Hepatol, 2023, 13(4): 608-617. DOI: 10.1016/j.jceh.2023.02.002.
[26] Liang W, Xu Z, Kong F, et al. Circulating tumour cell combined with DNA methylation for early detection of hepatocellular carcinoma [J]. Front Genet, 2022, 13: 1065693. DOI: 10.3389/fgene.2022.1065693.
[27] El-Mezayen HA, El -Kassas M, El-Taweel FM, et al. Diagnostic performance of circulating tumor cells for predicting of hepatocellular carcinoma in hepatitis c virus-high risk patients: role of liquid biopsy[J]. Asian Pac J Cancer Prev, 2022, 23(7): 2541-2549. DOI: 10.31557/APJCP.2022.23.7.2541.
[28] Zhao X, Zhao J, Tao L, et al. Significance of circulating tumor cells in the portal vein regarding metastases and vascular invasion in hepatocellular carcinoma patients [J]. J Gastrointest Oncol, 2021, 12(6):3050-3060. DOI: 10.21037/jgo-21-734.
[29] Prasoppokakorn T, Buntho A, Ingrungruanglert P, et al. Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma [J]. Sci Rep, 2022, 12(1): 18686. DOI: 10.1038/s41598-022-21888-9.
[30] Lu Z, Ni H, Yang X, et al. Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy [J]. BMC Cancer, 2023, 23(1): 1150. DOI: 10.1186/s12885-023-11629-0.
[31] Kocheise L, Schoenlein M, Behrends B, et al. EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma [J]. Sci Rep, 2023, 13(1):20827. DOI: 10.1038/s41598-023-47580-0.
[32] Yu JJ, Li YN, Shu C, et al. Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis[J]. J Cancer Res Clin Oncol, 2023, 149(11): 8981-8991. DOI: 10.1007/s00432-023-04834-8.

循环肿瘤细胞在肝细胞癌中的临床应用研究进展

Research progress of clinical application of circulating tumor cells in hepatocellular carcinoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.
[2]	刘晓琳陈铃陈欣欣梁伟翔. 自动乳腺容积超声成像在BI-RADS 4A类乳腺结节诊断中的价值 [J]. 国际医药卫生导报, 2024, 30(9): 1469-1473.
[3]	徐田田. 肾轻链沉积病伴多浆膜腔积液1例 [J]. 国际医药卫生导报, 2024, 30(9): 1552-1555.
[4]	郭江红王欢吴妍. LTBP-2联合心肺联合超声预测老年急性心肌梗死患者短期预后的价值 [J]. 国际医药卫生导报, 2024, 30(8): 1233-1238.
[5]	杨星王秋茹周雪. 脂蛋白a和载脂蛋白B联合维生素D检测对冠心病严重程度及短期预后的评估价值 [J]. 国际医药卫生导报, 2024, 30(8): 1238-1242.
[6]	聂海华李茂查李阳. 超急性期心肌梗死患者心电图特点分析 [J]. 国际医药卫生导报, 2024, 30(8): 1282-1285.
[7]	洪晓芳胡玉娟杨鹏凤周琼娟沈鸿源宋思仪宋础均梁伟翔刘韬. 颈动脉血管超声与CTA在颈动脉狭窄诊断中结果不一致的原因分析 [J]. 国际医药卫生导报, 2024, 30(8): 1334-1338.
[8]	吴鹏杨鸿炜李朝杰. 经肛门内镜下黏膜剥离术治疗早期直肠癌患者的效果观察 [J]. 国际医药卫生导报, 2024, 30(7): 1181-1185.
[9]	吴媛媛刘科齐艳丽童小华. 非小细胞肺癌组织中CLCA4的表达情况及与病理和预后的关系 [J]. 国际医药卫生导报, 2024, 30(6): 903-907.
[10]	曹喆霍亚玲王丹. 睾丸肾上腺残基瘤的超声图像特征 [J]. 国际医药卫生导报, 2024, 30(6): 1018-1020.
[11]	田燕袁权王虎霞惠金子段绍雪. ABUS联合血清VEGF、CEA对乳腺癌的诊断价值 [J]. 国际医药卫生导报, 2024, 30(5): 740-743.
[12]	陈锡莲杨勇卫王鹏雁刘友德潘伟. HBV相关原发肝细胞癌患者T淋巴细胞、壳酶蛋白和DR-70表达水平差异 [J]. 国际医药卫生导报, 2024, 30(5): 744-747.
[13]	张国坤张天佑张景畅李素新. 原发性肝癌患者TACE预后不良的因素分析：基于PSM法 [J]. 国际医药卫生导报, 2024, 30(5): 747-753.
[14]	路晓雯刘梓洋. 增强CT联合超声造影在HCC患者TACE疗效评估中的应用 [J]. 国际医药卫生导报, 2024, 30(5): 754-758.
[15]	王海峰吴照锋侯中玉李亮. 葡萄球菌相关PS患者临床特征及预后分析 [J]. 国际医药卫生导报, 2024, 30(5): 834-838.